TransMedics Group’s (NASDAQ:TMDX) lock-up period is set to expire on Tuesday, October 29th. TransMedics Group had issued 5,690,000 shares in its public offering on May 2nd. The total size of the offering was $91,040,000 based on an initial share price of $16.00. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Separately, Zacks Investment Research raised shares of TransMedics Group from a “sell” rating to a “hold” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $37.00.
Shares of TMDX opened at $17.80 on Thursday. The company’s 50 day simple moving average is $21.31. The company has a debt-to-equity ratio of 0.48, a quick ratio of 6.82 and a current ratio of 7.55. TransMedics Group has a twelve month low of $16.92 and a twelve month high of $31.54.
TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.29). The company had revenue of $5.67 million for the quarter, compared to analysts’ expectations of $5.59 million. Analysts predict that TransMedics Group will post -2.25 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in TMDX. Roubaix Capital LLC lifted its position in TransMedics Group by 24.8% during the 3rd quarter. Roubaix Capital LLC now owns 213,581 shares of the company’s stock worth $5,073,000 after buying an additional 42,408 shares in the last quarter. River & Mercantile Asset Management LLP bought a new stake in TransMedics Group during the 2nd quarter worth about $714,000. Zimmer Partners LP bought a new stake in TransMedics Group during the 2nd quarter worth about $15,612,000. Citadel Advisors LLC bought a new stake in TransMedics Group during the 2nd quarter worth about $1,281,000. Finally, First Light Asset Management LLC bought a new stake in TransMedics Group during the 2nd quarter worth about $783,000. 65.89% of the stock is currently owned by institutional investors.
About TransMedics Group
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
Recommended Story: Why does the United States have a lingering trade deficit?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.